Table 2.
SMART cost-effectiveness.
| Cohort analysis | Microsimulation | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Strategy | Cost | Incremental Cost | Effectiveness (QALY) | Incremental effectiveness | ICER | NMB | C/E | Strategy | Fatality | |
| Sum | Per patient SD | |||||||||
| 0.2% Risk for SCA (per annum) societal perspective | 0.2% Risk for SCA | |||||||||
| Not SMART | $2,106 | 20.66037 | $2,063,931 | $102 | Not SMART (n = 1,000) | 6,172 | 0.24 | |||
| SMART | $7,503 | $5,397 | 20.66857 | 0.00820 | $657,886 | $2,059,355 | $363 | SMART (n = 1,000) | 6,046 | 0.24 |
| 0.2% Risk for SCA (per annum) healthcare perspective | SMART SCA deaths prevented | 126 | ||||||||
| Not SMART | $214 | 20.66037 | $2,065,823 | $10 | ||||||
| SMART | $5,655 | $5,441 | 20.66857 | 0.00820 | $663,226 | $2,061,202 | $274 | |||
| 1.6% Risk for SCA (per annum) societal perspective | 1.6% Risk for SCA | |||||||||
| Not SMART | $14,881 | 17.06670 | $1,691,789 | $872 | Not SMART (n = 1,000) | 39,607 | 0.49 | |||
| SMART | $19,618 | $4,737 | 17.11643 | 0.04973 | $95,251 | $1,692,025 | $1,146 | SMART (n = 1,000) | 38,893 | 0.49 |
| 1.6% Risk for SCA (per annum) healthcare perspective | SMART SCA deaths prevented | 714 | ||||||||
| Not SMART | $1,439 | 17.06670 | $1,705,231 | $84 | ||||||
| SMART | $6,452 | $5,013 | 17.11643 | 0.04973 | $100,797 | $1,705,191 | $377 | |||
| 3.5% Risk for SCA (per annum) societal perspective | 3.5% Risk for SCA | |||||||||
| Not SMART | $27,858 | 13.55247 | $1,327,389 | $2,056 | Not SMART (n = 1,000) | 65,349 | 0.48 | |||
| SMART | $31,990 | $4,132 | 13.62909 | 0.07662 | $53,925 | $1,330,920 | $2,347 | SMART (n = 1,000) | 64,427 | 0.48 |
| 3.5% Risk for SCA (per annum) healthcare perspective | SMART SCA deaths prevented | 922 | ||||||||
| Not SMART | $2,547 | 13.55247 | $1,352,700 | $188 | ||||||
| SMART | $7,119 | $4,572 | 13.62909 | 0.07662 | $59,672 | $1,355,790 | $522 | |||
QALY, quality-adjusted life year; ICER, incremental cost-effectiveness ratio; NMB, net-monetary benefit synthesis of QALY and costs at a conversion rate of $100,000 per QALY; C/E, cost-effectiveness.